Navigation Links
Regulus Reports Third Quarter 2013 Financial Results and Recent Highlights
Date:11/13/2013

LA JOLLA, Calif., Nov. 13, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the quarter ended September 30, 2013 and provided a summary of recent corporate highlights. 

"This was a remarkably productive third quarter and recent period for Regulus in which we focused on scientific execution and demonstrated significant progress across our microRNA therapeutic pipeline.  Our 'Road to the Clinic' strategy remains on track and we are working towards filing our first application with regulatory authorities to commence clinical studies in man of RG-101, our GalNAc-conjugated anti-miR targeting miR-122, for hepatitis C virus infection.  We believe this program will condition Regulus for future clinical activities and may provide proof-of-concept, possibly by the end of next year, for our innovative approach to treating disease with microRNA therapeutics," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus.  "In addition, our strategic alliance partners continue to support our expertise in discovering and developing new microRNA therapeutics, as evidenced by the recent selection of a new, pre-clinically validated oncology target by AstraZeneca.  We also continue to focus our proprietary efforts on oncology and orphan diseases and look forward to identifying attractive new opportunities to broaden our pipeline. We're very pleased with our progress and hope to carry our positive momentum into the end of the year and into 2014."

"The significant achievements in the quarter and recent period demonstrate that our science continues to advance in a meaningful way," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus.&
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
2. Regulus Announces Timing for Third Quarter 2013 Financial Results Webcast and Conference Call
3. Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated microRNA Oncology Target
4. Regulus Reports Second Quarter 2013 Financial Results and Recent Highlights
5. Regulus Announces Timing for Second Quarter 2013 Financial Results Webcast and Conference Call
6. Regulus Names Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors
7. Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference
8. Regulus Provides Update on Road to the Clinic Strategy and Reports First Quarter 2013 Financial Results and Recent Highlights
9. Regulus Announces Timing for First Quarter 2013 Financial Results Webcast and Conference Call
10. Regulus Appoints William H. Rastetter, Ph.D. to its Board of Directors
11. Regulus to Present at Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014   Rock Creek Pharmaceuticals, Inc., ... is scheduled to present at the Biotech Showcase™ 2015 ... on January 12-14, 2015. ... Rock Creek Pharmaceuticals, will present preclinical and clinical data ... exhibits anti-inflammatory pharmacological characteristics. Dr. Mullan will outline the ...
(Date:11/21/2014)... 21. November 2014 ... bekannt gegeben, dass die Europäische Arzneimittel-Agentur ... Kennzeichnung als Orphan-Medizinprodukt an Palovarotene vergeben ... zur Behandlung von Fibrodysplasia ossificans progressiva ... beeinträchtigende genetische Krankheit, die von schmerzhaften, ...
(Date:11/21/2014)... 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) ... Officer, will be presenting at the 26 th Annual ... in New York . The formal presentation ... ET. In addition, Mr. Krakauer and Jorgen B. Hansen ... meetings during the day. An audio webcast ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... ATLANTA, May 25, 2011 XDATA retains Adapt ... patents and fully-functioning prototype focused on breast cancer ... and tested methods and devices for automatically capturing ... validation of the value of XDATA,s patents, leading ...
... as a sort of Huffington Post for the Medical ... offering "Your One Source For Growing Medical Marijuana" for ... worldwide. This first of its kind web ... growing Medical Marijuana and the lifestyle that has arisen ...
Cached Medicine Technology:XDATA Retains Adapt IP Ventures to Market Patents and Technology for Automated 3D Ultrasound Imaging System 2
(Date:11/21/2014)... Mo (PRWEB) November 21, 2014 ... the Get With The Guidelines®–Heart Failure Gold-Plus Quality ... outlined by the American Heart Association/American College of ... heart failure patients. , Get With The Guidelines–Heart ... hospital teams provide the most up-to-date, research-based guidelines ...
(Date:11/21/2014)... VA (PRWEB) November 21, 2014 Launched ... App (ECA) is an all-in-one senior care coordination tool ... on loved ones simple and intuitive for family members ... day care centers). Now, the family caregiver or home ... their daily activities, health data, medical records, goals, schedules, ...
(Date:11/21/2014)... DressVe.com , a renowned women’s dress wholesaler and retailer in ... accessories. Furthermore, the company has launched its Special Black Friday ... its fashion items. Also, orders above $59 are qualified for ... their wedding dresses and prom dresses are very popular in ... , The CEO says “We are glad to introduce ...
(Date:11/21/2014)... 2014 CARE Surrogacy Center in Mexico ... — and at the same time enhancing their surrogacy journey ... for future parents across the globe, the company is reporting ... today are zoning in on the skyrocketing costs of surrogacy ... are individuals over-stressing clinical success rates ? , ...
(Date:11/21/2014)... London, UK (PRWEB) November 21, 2014 ... world’s only ISO verified healthcare professional panel, today announced two ... the appointment of Roni DasGupta as President of Market Research, ... of Market Research, Europe. , Ms. DasGupta joined ... Vice President and most recently Head of Sales. Roni ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 4Health News:Comprehensive Senior Care Application Launched on Apple App Store 2Health News:DressVe.com Announces Its 2014 Special Friday Sales 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 3Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2
... pneumonia and gastrointestinal woes , , THURSDAY, Oct. 30 (HealthDay ... age 65 and older resulted in medical and lost ... researchers who analyzed Medicare and National Health Interview Survey ... study were: chronic lung disease, ischemic heart disease, stroke, ...
... 30 Palomar Medical,Technologies, Inc. (Nasdaq: PMTI ... for cosmetic treatments, today announced financial,results for the ... the,quarter ended September 30, 2008 were $24.2 million, ... were royalty revenues, $1.0 million,were funded development revenues, ...
... to Eat Right, Move More and ... Milk Their Diets, ATLANTA, Oct. ... different fad diets -- which seem to go in and out of,fashion like ... Americans -- including 56 percent of Georgia,residents -- remain overweight or obese., ...
... Oct. 30 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: MBRK ... novel anti-infective products, is scheduled,to announce its financial ... Nov. 13, 2008, before the market opens. At ... conduct a conference call to review the,Company,s third ...
... Ariz., Oct. 30 NaturalNews.com, the independent,natural ... million health-conscious,consumers, has posted audio interviews with ... "Home Safe Home," and Byron Richards, founder ... supplement,provider. Both interviews are available as free ...
... attack rates change when clocks are adjusted , , WEDNESDAY, Oct. ... is just about here, and it may pose problems more ... a jump in the number of heart attacks following the ... spring. , "This was the very first study on this ...
Cached Medicine News:Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 2Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 3Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 4Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 5Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 6Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 7Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 8Health News:Palomar Medical Reports Financial Results for Third Quarter 2008 9Health News:Message to Georgia Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Georgia Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Georgia Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results 2Health News:NaturalNews Posts Audio Interview with Consumer Chemical Expert Debra Lynn Dadd on Bisphenol-A 2Health News:Semi-Annual Time Changes May Affect the Heart 2Health News:Semi-Annual Time Changes May Affect the Heart 3
... basic principle of a competitive enzyme immunoassay ... antigen and an labelled antigen bound to ... antiserum . The amount of enzyme conjugate ... antibody is inversely proportional to the concentration ...
... Progesterone (pregn-4-ene-3, 20-dione) is a C21 ... a double bond between C-4 and C-5 ... hormone which, in conjunction with estrogens, regulates,the ... it is particularly important in preparing the,endometrium ...
Microalbumin Turbidimetric Lipid / Protein Quantification 021-SDX001...
... known as Kininase II, is a dipeptidyl ... of at least 129,000. The structure of ... a polysaccharide residue and a zinc atom. ... types such as neuronal cells and renal ...
Medicine Products: